NASDAQ
0.98USD
-0.05 (-5.15%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
124.3M
P/E
—
EPS
—
Beta
0.81
52W range
0.62-4.31
Day range
0.95–1.06
Open
1.03
Prev close
1.03
Volume
925K
Avg volume
749.5K
Dividend
0.00
IPO
2020-08-07
https://seekingalpha.com/article/4929390-nautilus-biotechnology-contrarian-proteoformics-play-after-the-recent-pullback · 8/3/2026-0.60
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome in the United States. The company develops Nautilus Voyager Platform, which includes an end-to-end solution comprising instruments, reagents, consumables, and software analysis. It also provides nautilus voyager instrument, a high-resolution optical imaging system with integrated fluidics and liquid handling sub-system to deposit protein libraries onto a flow cell and to process labeled multi-affinity reagent binding and imaging cycles rapidly to decode and quantify the proteins present in biological samples. In addition, the company offers single-molecule library preparation kits, flow cells, affinity reagents, and instrument run buffers to perform multi-cycle analysis runs. It has a research collaboration agreement Genentech, Buck Institute, Allen Institute, Cornell University and the Qatar Foundation, and Michael J. Fox Foundation. Nautilus Biotechnology, Inc. was founded in 2016 and is headquartered in Seattle, Washington.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
